tiprankstipranks
Telix Pharmaceuticals Ltd. (AU:TLX)
ASX:TLX
Australian Market
TLX
Telix Pharmaceuticals
RESEARCH TOOLSreports

Telix Pharmaceuticals (TLX) Share Forecast & Price Target

580 Followers
See the Price Targets and Ratings of:

TLX Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Telix
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TLX Stock 12 Month Forecast

Average Price Target

AU$24.52
▲(79.78% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is AU$24.52 with a high forecast of AU$32.00 and a low forecast of AU$18.00. The average price target represents a 79.78% change from the last price of AU$13.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"AU$8","33":"AU$33","14.25":"AU$14.25","20.5":"AU$20.5","26.75":"AU$26.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.52222222222222,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$24.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,14.25,20.5,26.75,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.2,14.646153846153846,16.092307692307692,17.538461538461537,18.984615384615385,20.43076923076923,21.876923076923077,23.323076923076922,24.769230769230766,26.215384615384615,27.661538461538463,29.107692307692307,30.553846153846152,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.2,14.07094017094017,14.94188034188034,15.812820512820512,16.68376068376068,17.554700854700855,18.425641025641024,19.296581196581194,20.167521367521367,21.038461538461537,21.909401709401706,22.78034188034188,23.65128205128205,{"y":24.52222222222222,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.2,13.569230769230769,13.938461538461539,14.307692307692307,14.676923076923076,15.046153846153846,15.415384615384616,15.784615384615385,16.153846153846153,16.52307692307692,16.892307692307693,17.26153846153846,17.630769230769232,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetAU$32.00Average Price TargetAU$24.52Lowest Price TargetAU$18.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on AU:TLX
Shane Storey
Canaccord Genuity
Canaccord Genuity
AU$30
Buy
119.94%
Upside
Reiterated
04/10/26
Telix Pharmaceuticals (TLPPF) Gets a Buy from Canaccord Genuity
Jefferies Analyst forecast on AU:TLX
David Stanton
Jefferies
Jefferies
AU$23.4→AU$24.3
Buy
78.15%
Upside
Reiterated
04/09/26
Analysts Offer Insights on Healthcare Companies: LeonaBio (NASDAQ: LONA), Telix Pharmaceuticals (Other OTC: TLPPF) and Chugai Pharmaceutical Co (Other OTC: CHGCF)
UBS Analyst forecast on AU:TLX
David Dai
UBS
UBS
AU$31
Buy
127.27%
Upside
Reiterated
04/08/26
Telix Pharmaceuticals (TLPPF) Gets a Buy from UBS
Bell Potter Analyst forecast on AU:TLX
John Hester
Bell Potter
Bell Potter
AU$19
Buy
39.30%
Upside
Reiterated
04/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (Other OTC: CMXHF) and Telix Pharmaceuticals (Other OTC: TLPPF)
Jarden Analyst forecast on AU:TLX
Steven Wheen
Jarden
Jarden
AU$21→AU$21.8
Buy
59.82%
Upside
Reiterated
04/07/26
Jarden Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
Morgan Stanley Analyst forecast on AU:TLX
David Bailey
Morgan Stanley
Morgan Stanley
AU$24.6
Buy
80.35%
Upside
Reiterated
04/07/26
Morgan Stanley Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
RBC Capital Analyst forecast on AU:TLX
Craig Wong-Pan
RBC Capital
RBC Capital
AU$17→AU$18
Buy
31.96%
Upside
Reiterated
04/07/26
Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM)
Citi Analyst forecast on AU:TLX
Laura Sutcliffe
Citi
Citi
AU$32
Buy
134.60%
Upside
Reiterated
03/16/26
Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Immutep Ltd (Other OTC: PRRUF)
TD Cowen Analyst forecast on AU:TLX
Tara Bancroft
TD Cowen
TD Cowen
AU$20
Buy
46.63%
Upside
Reiterated
02/19/26
Telix: Dual-Product PSMA Strategy and Cash-Generating Diagnostics Base Support Buy Rating and Multibillion-Dollar Therapeutics Upside
Ord Minnett Analyst forecast on AU:TLX
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
AU$22.6
Buy
65.69%
Upside
Reiterated
10/15/25
Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett
CLSA Analyst forecast on AU:TLX
Andrew Paine
CLSA
CLSA
AU$24.25
Buy
77.79%
Upside
Reiterated
10/03/25
CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on AU:TLX
Shane Storey
Canaccord Genuity
Canaccord Genuity
AU$30
Buy
119.94%
Upside
Reiterated
04/10/26
Telix Pharmaceuticals (TLPPF) Gets a Buy from Canaccord Genuity
Jefferies Analyst forecast on AU:TLX
David Stanton
Jefferies
Jefferies
AU$23.4→AU$24.3
Buy
78.15%
Upside
Reiterated
04/09/26
Analysts Offer Insights on Healthcare Companies: LeonaBio (NASDAQ: LONA), Telix Pharmaceuticals (Other OTC: TLPPF) and Chugai Pharmaceutical Co (Other OTC: CHGCF)
UBS Analyst forecast on AU:TLX
David Dai
UBS
UBS
AU$31
Buy
127.27%
Upside
Reiterated
04/08/26
Telix Pharmaceuticals (TLPPF) Gets a Buy from UBS
Bell Potter Analyst forecast on AU:TLX
John Hester
Bell Potter
Bell Potter
AU$19
Buy
39.30%
Upside
Reiterated
04/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (Other OTC: CMXHF) and Telix Pharmaceuticals (Other OTC: TLPPF)
Jarden Analyst forecast on AU:TLX
Steven Wheen
Jarden
Jarden
AU$21→AU$21.8
Buy
59.82%
Upside
Reiterated
04/07/26
Jarden Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)
Morgan Stanley Analyst forecast on AU:TLX
David Bailey
Morgan Stanley
Morgan Stanley
AU$24.6
Buy
80.35%
Upside
Reiterated
04/07/26
Morgan Stanley Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
RBC Capital Analyst forecast on AU:TLX
Craig Wong-Pan
RBC Capital
RBC Capital
AU$17→AU$18
Buy
31.96%
Upside
Reiterated
04/07/26
Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), Mirum Pharmaceuticals (MIRM)
Citi Analyst forecast on AU:TLX
Laura Sutcliffe
Citi
Citi
AU$32
Buy
134.60%
Upside
Reiterated
03/16/26
Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Immutep Ltd (Other OTC: PRRUF)
TD Cowen Analyst forecast on AU:TLX
Tara Bancroft
TD Cowen
TD Cowen
AU$20
Buy
46.63%
Upside
Reiterated
02/19/26
Telix: Dual-Product PSMA Strategy and Cash-Generating Diagnostics Base Support Buy Rating and Multibillion-Dollar Therapeutics Upside
Ord Minnett Analyst forecast on AU:TLX
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
AU$22.6
Buy
65.69%
Upside
Reiterated
10/15/25
Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett
CLSA Analyst forecast on AU:TLX
Andrew Paine
CLSA
CLSA
AU$24.25
Buy
77.79%
Upside
Reiterated
10/03/25
CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Telix Pharmaceuticals

3 Months
xxx
Success Rate
13/17 ratings generated profit
76%
Average Return
+23.76%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 76.47% of your transactions generating a profit, with an average return of +23.76% per trade.
1 Year
Steven WheenJarden
Success Rate
17/24 ratings generated profit
71%
Average Return
+44.47%
Copying Steven Wheen's trades and holding each position for 1 Year would result in 70.83% of your transactions generating a profit, with an average return of +44.47% per trade.
2 Years
xxx
Success Rate
10/18 ratings generated profit
56%
Average Return
+35.62%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +35.62% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLX Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
19
18
25
31
25
Buy
1
0
1
1
3
Hold
1
1
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
19
27
32
28
In the current month, TLX has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TLX average Analyst price target in the past 3 months is 24.52.
Each month's total comprises the sum of three months' worth of ratings.

TLX Financial Forecast

TLX Earnings Forecast

Next quarter’s earnings estimate for TLX is AU$0.03 with a range of AU$0.03 to AU$0.03. The previous quarter’s EPS was -AU$0.02. TLX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TLX has Performed in-line its overall industry.
Next quarter’s earnings estimate for TLX is AU$0.03 with a range of AU$0.03 to AU$0.03. The previous quarter’s EPS was -AU$0.02. TLX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TLX has Performed in-line its overall industry.

TLX Sales Forecast

Next quarter’s sales forecast for TLX is AU$333.53M with a range of AU$329.20M to AU$336.27M. The previous quarter’s sales results were AU$630.94M. TLX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TLX has Performed in-line its overall industry.
Next quarter’s sales forecast for TLX is AU$333.53M with a range of AU$329.20M to AU$336.27M. The previous quarter’s sales results were AU$630.94M. TLX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TLX has Performed in-line its overall industry.

TLX Stock Forecast FAQ

What is AU:TLX’s average 12-month price target, according to analysts?
Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 24.52.
    What is AU:TLX’s upside potential, based on the analysts’ average price target?
    Telix Pharmaceuticals Ltd. has 79.78% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Telix Pharmaceuticals Ltd. a Buy, Sell or Hold?
          Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy, which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Telix Pharmaceuticals Ltd.’s share price target?
            The average share price target for Telix Pharmaceuticals Ltd. is 24.52. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is AU$32.00 ,and the lowest forecast is AU$18.00. The average share price target represents 79.78% Increase from the current price of AU$13.64.
              What do analysts say about Telix Pharmaceuticals Ltd.?
              Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of Telix Pharmaceuticals Ltd.?
                To buy shares of AU:TLX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.